Barrington Research Raises LeMaitre Vascular (NASDAQ:LMAT) Price Target to $79.00

LeMaitre Vascular (NASDAQ:LMAT) had its price objective raised by Barrington Research from $69.00 to $79.00 in a research report report published on Friday, Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and increased their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. KeyCorp started coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a sector weight rating for the company. Finally, StockNews.com downgraded LeMaitre Vascular from a buy rating to a hold rating in a research note on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $73.83.

LeMaitre Vascular Stock Up 1.1 %

Shares of NASDAQ LMAT traded up $0.78 during mid-day trading on Friday, hitting $75.00. 523,367 shares of the company traded hands, compared to its average volume of 121,377. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $76.24. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 50.18, a PEG ratio of 2.99 and a beta of 0.88. The business has a 50 day moving average of $65.93 and a two-hundred day moving average of $58.85.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same period in the prior year, the business posted $0.27 earnings per share. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. As a group, research analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.85%. The ex-dividend date is Wednesday, May 15th. LeMaitre Vascular’s payout ratio is currently 42.38%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 36,600 shares of LeMaitre Vascular stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at $148,817,393.78. The disclosure for this sale can be found here. Insiders have sold a total of 114,036 shares of company stock valued at $7,873,749 in the last three months. Insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently made changes to their positions in the company. Shaker Investments LLC OH lifted its stake in LeMaitre Vascular by 1.3% during the first quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 169 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after acquiring an additional 187 shares in the last quarter. Riverwater Partners LLC boosted its holdings in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 198 shares in the last quarter. Albion Financial Group UT boosted its holdings in shares of LeMaitre Vascular by 5.6% during the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after acquiring an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp boosted its holdings in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after acquiring an additional 225 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.